Be part of the knowledge.™

Pioglitazones in NASH

Media Formats

ReachMD Healthcare Image

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Presenters

Overview
Nonalcoholic steatohepatitis, or NASH, is a common, often "silent" liver disease. Join us as we discuss surprising effects that pioglitazones have in NASH.

Kenneth Cusi, MD, FACP, FACE

Kenneth Cusi, MD, FACP, FACE

Larry Kaskel, MD

Larry Kaskel, MD

Recommended

Details

Presenters

Overview
Nonalcoholic steatohepatitis, or NASH, is a common, often "silent" liver disease. Join us as we discuss surprising effects that pioglitazones have in NASH.

Kenneth Cusi, MD, FACP, FACE

Kenneth Cusi, MD, FACP, FACE

Larry Kaskel, MD

Larry Kaskel, MD

Program Chapters

Segment Chapters

Playlist:

Recommended

Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective

I'm Getting the Hang of This! I Have Two Patients: One At 'Indeterminate Risk' and One At 'High Risk' for Clinically Significant Fibrosis

M3: Managing the Cardiometabolic Risk in MASH

CME/CE Broadcast Replay

Love Story: Lipid Education for Women’s Heart Health

Best Practices for Identifying, Diagnosing and Treating Transthyretin Amyloidosis (ATTR-PN and ATTR-CM)

HF Management for Patients with Comorbid Conditions

Level Up Your Skills: Tailoring Management of HF

Clinical Conundrums in ARIA: Communicating ARIA Risk with Patients Considering Anti-Aβ Therapy